Sunitinib-induced reversible posterior leukoencephalopathy syndrome after rifampin discontinuation / 대한내과학회지
Korean Journal of Medicine
; : S188-S191, 2009.
Article
in Korean
| WPRIM (Western Pacific)
| ID: wpr-139798
Responsible library:
WPRO
ABSTRACT
Sunitinib is an oral tyrosine kinase inhibitor with anti-angiogenic activity that is used for the treatment of advanced renal cell carcinoma and advanced gastrointestinal stromal tumors after failure on imatinib. The most common adverse effects of sunitinib are fatigue, diarrhea, nausea, stomatitis, hypertension, hand-foot syndrome, and cytopenia. Sunitinib was recently reported to be associatedwith reversible posterior leukoencephalopathy syndrome (RPLS). Here, we report the case of a 76-year-old woman with sunitinib- induced RPLS that developed after rifampin discontinuation.
Full text:
Available
Health context:
Neglected Diseases
Health problem:
Diarrhea
/
Neglected Diseases
Database:
WPRIM (Western Pacific)
Main subject:
Piperazines
/
Pyrimidines
/
Pyrroles
/
Rifampin
/
Stomatitis
/
Benzamides
/
Protein-Tyrosine Kinases
/
Carcinoma, Renal Cell
/
Gastrointestinal Stromal Tumors
/
Diarrhea
Limits:
Aged
/
Female
/
Humans
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2009
Document type:
Article